You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Triagonist Peptide Therapeutics for Neuroprotection

    SBC: VELUM INC            Topic: 300

    Project Summary Morbidity associated with neuronal degeneration and dysfunction poses an increasing public health burden. Among the wide range of etiologies that result in neuronal dysfunction, including chronic conditions such as Alzheimer’s and Parkinson’s disease and vascular dementias, one major cause that has been largely unnoticed but is increasingly recognized as a major concern is trau ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Ultrahigh Throughput Microscale Mass Spectrometry for Pharmaceutical Prenylation Enzyme Engineering

    SBC: Fluid Discovery Inc            Topic: 400

    Project Summary Biocatalyst can be key tools in the synthesis of natural product-based pharmaceuticals and as powerful components of the pharmaceutical chemist’s drug modification kit. For example, the aromatic prenyltransferase NphB has utility in the synthesis of common prenylated compounds or derived backbones include cannabinoids, alpha acids, beta acids, phenylpropanoids, naphterpins, and m ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media

    SBC: OSSIUM HEALTH INC            Topic: 400

    ABSTRACT:The tremendous cost of cell-based therapies manufacturing is the significant threat to the success of cell/gene therapy treatments. The cell culture medium alone can contribute to around 30-40% of the Cost of Goods (COGs). This is because, the current cell culture methods require frequent and complete media replacement in order to remove toxic metabolites from culture. This practice of co ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Small Molecule Antagonists of PAR-2 for treatment of asthma

    SBC: PARMEDICS, INC            Topic: NHLBI

    ABSTRACT: Current treatments for asthma largely are aimed at reducing exacerbations by directly treating airway inflammation. While successful in a subset of patients, asthma exacerbations remain a significant cause of morbidity and mortality and can result in airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Exhaled breath drug detection using differential mobility spectrometry

    SBC: VOX BIOMEDICAL LLC            Topic: NIDA

    Project Summary We have conducted a pilot study using some of the elements in the present proposal that provide support for the notion that a well selected set of psychomotor/performance tasks can be used to predict driving impairment via a simulated program. Adding these two approaches to the existing STTR project will add significantly to the value of the data focused on developing a breath test ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Engineered Cyclodextrins to Address 7-ketocholesterol-Associated Diseases ofAging

    SBC: UNDERDOG PHARMACEUTICALS, INC.            Topic: NIA

    Project Summary/Abstract Underdog Pharmaceuticals, Inc. (UDP), in collaboration with the SENS Research Foundation (SRF), aims to demonstrate that 7-ketocholesterol (7KC) is elevated in red blood cells (RBCs) in Atherosclerosis and Alzheimer’s disease. 7KC is primarily created by non-enzymatic oxidation of cholesterol. With only a few exceptions, human tissues lack the ability to metabolize or ex ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Mindfulness Based Stress Reduction Application for African American Caregivers

    SBC: COG ANALYTICS, LLC            Topic: NIA

    AbstractThere are approximately 43.5 million informal (unpaid) caregivers in the U.S., of which 5.6 million are African American. Informal caregivers often provide a variety of types of support including emotional, physical, and financial, to people with chronic conditions.1 Providing care can be very stressful and emotionally and physically exhausting for informal caregivers.2 African American ca ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    SBC: VELUM INC            Topic: NIA

    Project Summary There is a world-wide “twin epidemic” of obesity and Type 2 Diabetes (T2D), with an urgent need to find effective new drug treatments for inducing weight loss. Stable derivatives of the endogenous glucoregulatory hormone, glucagon-like peptide-1 (GLP1) are in clinical use for the treatment of T2D but are also of great interest as an emerging treatment of obesity. Another closel ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Development of perivascular space mapping toolset as a diagnostic aid for Alzheimer's disease

    SBC: NEUROSCOPE INC.            Topic: NIA

    Project Summary Alzheimer’s disease (AD) is a devastating disease that affects millions of Americans and imposes a huge socio- economic burden. AD-related cognitive decline is associated with the accumulation of Aβ (Amyloid beta) plaques and neurofibrillary tangles of hyperphosphorylated tau protein, which are insufficiently cleared and degraded by mechanisms such as the glia-lymphatic system o ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Multi-modal cloud based system for detecting early signs of driver cognitive decline and/or high risk driving behaviors

    SBC: PHYSICAL SCIENCES INC.            Topic: NIA

    Project Summary/AbstractPhysical Sciences Inc. (PSI), in collaboration with Michigan State University (MSU) and the University of Michigan (U-M), proposes to develop a novel technology that will non-intrusively monitor driver cognitive decline and/or high-risk driving behavior that is especially suited for seniors (aged andgt;65). Contextual physiological biomarkers along with computer vision base ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government